Inactive Instrument

Highlights Pieris Pharmaceuticals Inc OTC Bulletin Board

Equities

PIRS

US7207951036

End-of-day quote OTC Bulletin Board Other stock markets
-	-

Apr. 19	Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	MT
Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	Apr. 19	MT
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference	23-05-21	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Reports Q1 Revenue $1.9 Million	23-05-10	MT
Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)	23-05-04	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
North American Morning Briefing : Focus This Week -3-	23-03-06	DJ
North American Morning Briefing : Stock Futures -3-	23-02-27	DJ
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)	23-01-10	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Reports Q3 Revenue $5.4M	22-11-02	MT
Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220	22-11-01	CI
Pieris Pharmaceuticals Q2 Loss Narrows, Revenue Rises; Shares Fall	22-08-04	MT
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Posts Q2 Revenue $3.7M	22-08-04	MT
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pieris Pharmaceuticals Inc OTC Bulletin Board

Equities

PIRS

US7207951036

Highlights

Filters